Speed, Integration, and the Future of Fill-Finish
What We’re Hearing Across Drug Product Development
Across recent conversations with clients, prospects, industry partners, sponsors, and investors, several priorities continue to stand out across the drug product development and the fill-finish landscape: speed, flexibility, regulatory confidence, and the need for more integrated support from clinical development through commercial manufacturing.
These priorities reflect a broader shift in how companies are evaluating CDMO partners. Available capacity remains important, but drug developers are increasingly looking for partners that can provide proven fill-finish experience, strong analytical capabilities, regulatory discipline, device assembly support, and continuity across the drug product lifecycle.
Recent conversations at industry events, including BIO International 2026 in San Diego, have reinforced these themes and provided valuable insight into what companies are prioritizing as their programs advance. One message continues to emerge clearly: drug developers are seeking CDMO partners that can combine speed, technical expertise, quality, and integrated support as programs progress from early clinical development toward commercial supply.
“The expectations facing drug developers continue to rise. Programs must move faster, navigate increasing complexity, and remain prepared for both regulatory and commercial milestones. Our responsibility at Pyramid is to bring together the experience, capabilities, and operational discipline needed to help clients advance with confidence.”
— Dirk Lange, CEO, Pyramid Pharma Services
Speed, Flexibility, and Proven Fill-Finish Experience
Many of the conversations we have had across recent client and industry engagements have centered around speed, reliability, and agility. As development programs continue to move quickly, companies are looking for partners that can respond with urgency while maintaining the discipline required for sterile manufacturing.
Another topic that continues to surface is the importance of selecting a CDMO with proven fill-finish experience. As programs become more complex and development timelines continue to compress, companies are placing greater value on partners with established sterile manufacturing expertise and a demonstrated track record of execution.
Experience is not simply about years in operation. It provides confidence that technical challenges can be anticipated, risks can be mitigated, and programs can continue moving forward without unnecessary delays.
These conversations reinforce a broader industry trend: while speed remains critical, it cannot come at the expense of quality or reliability. Drug developers are looking for partners that combine technical expertise, robust quality systems, and operational excellence to help navigate the complexities of sterile manufacturing and successfully advance products from clinical development to commercial supply.
Regulatory Confidence Remains a Key Priority
Regulatory readiness continues to be a recurring theme in conversations with drug developers. Many discussions center on quality systems, inspection history, and how CDMOs maintain a state of inspection readiness throughout a product’s lifecycle.
These conversations have also led to questions about Pyramid’s most recent FDA inspection in February and our approach to maintaining a strong quality culture.
More importantly, these discussions reflect a broader industry priority. As programs advance toward pivotal studies and commercialization, drug developers are placing increasing emphasis on partnering with CDMOs that demonstrate consistent regulatory compliance, robust quality systems, and a proven ability to support successful inspections. Regulatory confidence is not viewed as a differentiator. It is an expectation that enables companies to move their programs forward with greater certainty.
For Pyramid, this continues to be an important part of who we are. Our commitment to quality and operational excellence remains central to the way we support client programs at every stage.
Analytical Roots and Integrated Support
Another theme that continues to emerge is the growing importance of integrated development and manufacturing support. As programs become more complex and timelines become increasingly compressed, many companies are looking to reduce handoffs between service providers and work with partners that can provide scientific continuity across multiple stages of development.
These conversations have highlighted the value of a strong analytical foundation. Pyramid first began as an analytical laboratory, and that foundation continues to shape the way we support client programs today.
When analytical expertise is closely connected with process development, fill-finish manufacturing, and lyophilization, teams are often better positioned to troubleshoot challenges, transfer knowledge efficiently, and make informed decisions as programs progress.
For drug developers, an integrated approach can help reduce complexity, improve communication across functions, and create a smoother path from development through clinical manufacturing and ultimately toward commercialization.
Clinical-to-Commercial Support and Device Assembly
Clinical-to-commercial support remains another important priority across the market. Many companies are thinking beyond their immediate development needs and looking for partners that can support them as their programs evolve.
Conversations around capacity, timeline flexibility, and commercial readiness continue to reinforce the need for CDMO partners that can support both clinical-stage agility and the expectations of later-stage manufacturing. At Pyramid, this is where our integrated capabilities continue to create value.
We also continue to see growing interest in device assembly and the need for coordinated support across the drug product lifecycle. Pyramid’s recent expansion in fully automated device assembly reflects the growing demand for partners that can support both sterile fill-finish and device assembly within an integrated manufacturing approach.
As more therapies are developed for administration in prefilled syringes, autoinjectors, and other delivery systems, drug developers are increasingly seeking partners that can help connect manufacturing strategy, product requirements, and patient-centered delivery needs. By expanding these capabilities, Pyramid is better positioned to support clients throughout the drug product lifecycle while helping them deliver innovative therapies to patients who depend on them.
Join Us at the Injectable Innovation Forum
Pyramid is looking forward to hosting the Injectable Innovation Forum on September 1, 2026, at our facilities in Costa Mesa, California. The event will bring together drug developers, technology providers, manufacturing experts, and other life sciences professionals for an afternoon of industry discussion, facility tours, tabletop exhibits, and networking focused on the future of injectable drug products.
The speaker lineup will include Evan Edwards, CEO of Kymanox; Valeria Leone, Business Development Director at Stevanato Group; Paul Martinez, Head of Business Development, Americas, at SHL Medical; Derek Kerr, Key Account Manager at Mikron Automation; a representative from Wheeler Bio; Brendan Cummings, Associate Director, Drug Delivery Device Development, Ionis Pharmaceuticals, Inc, and Dirk Lange, CEO of Pyramid Pharma Services.
Attendees will also have the opportunity to connect with participating organizations at tabletop exhibits hosted by Wheeler Bio, AGC Biologics, SHL Medical, Mikron Automation, Stevanato Group, Ionis Pharmaceuticals, Inc, and Pyramid Pharma Services.
Through presentations, exhibits, facility tours, and meaningful industry conversations, the forum will explore emerging trends across sterile fill-finish, injectable drug delivery, device assembly, and clinical-to-commercial manufacturing. The event is designed to create a dedicated setting for discussing the technologies, partnerships, and manufacturing strategies shaping the future of injectable therapies.
We look forward to welcoming members of the Southern California life sciences community and continuing the conversations that help move innovative drug products forward.
Register here for the Injectable Innovation Forum
Industry Events as a Place for Meaningful Conversation
While formal meetings remain an important part of industry conferences, some of the most productive conversations often happen in more informal settings. Events like BIO and CPHI create valuable opportunities to hear firsthand from drug developers, sponsors, investors, and partners about the challenges shaping today’s development and manufacturing decisions.
At BIO International 2026, Pyramid created several spaces designed to encourage these conversations. Our coffee bar brought consistent traffic to the booth throughout the week and created a natural setting for discussions with clients, prospects, and industry peers. Our happy hour also gave attendees the opportunity to connect with our team in a more relaxed setting, while the photo booth added a fun and memorable element to the week.
We were also proud to host our “All Roads Lead to Pyramid” scavenger hunt with YUMAB, ExcellGene, Wheeler Bio, and Bionova. The scavenger hunt gave participants an interactive way to learn about the drug development journey, from early-stage development through drug product. Each participating organization helped highlight a different stage of the process, creating an engaging experience that connected education, collaboration, and industry partnership.
Continuing the Momentum
The conversations we continue to have across the industry reinforce the same priorities: speed, proven fill-finish expertise, regulatory confidence, integrated support, and flexible clinical-to-commercial manufacturing solutions.
As Pyramid looks ahead, we remain focused on supporting clients with the capabilities, quality systems, and technical expertise needed to move programs forward with confidence.
Our team will be attending several upcoming industry events this fall, including Contract Pharma in New Brunswick, New Jersey, from September 24–26, 2026; CPHI Milan in Milan, Italy, from October 6–8, 2026; and PODD in Boston, Massachusetts, from October 29–30, 2026.
Pyramid will also be sponsoring the Boulder Peptide Symposium in Boulder, Colorado, from September 28–October 1, 2026.
If you are planning to attend any of these upcoming events, we would welcome the opportunity to connect and discuss how Pyramid can support your sterile fill-finish, analytical, lyophilization, device assembly, and clinical-to-commercial manufacturing needs.
We look forward to continuing the conversation.
